NCT06126653Phase 2Completed
A Study to Evaluate ARD-501 in Patients With Autism Spectrum Disorder
Study sponsor: Aardvark Therapeutics, Inc. · AARD
Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.
Primary completion2025-01-13Actual
Enrollment · participants5Actual
Source updated2025-05-09Last update listed in the registry record
Version history
Changes to this trial
Pro unlocks the full available history and CSV export. View Pro features
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.